NEWS
Alex Brill Speaks on Consequences of Proposed PBM Constraints
In December, MGA CEO Alex Brill participated in a RealClearPolitics event looking at the negative consequences of limiting the business practices of PBMs.
Patent Thicket Remedies
Yesterday, the Initiative for Medicines, Access, and Knowledge I-MAK took an important step by proposing six policy solutions to address patent thickets that block generic and biosimilar drug competition.
This Corporate Law Case Could Accidentally Overturn U.S. Taxes
This week, the Supreme Court will hear oral arguments in Moore v. United States, a case that centers on the mandatory repatriation tax (MRT).
Don’t Mix US Tax Administration Policy with the Israel-Hamas Conflict
House lawmakers are expected to vote soon on an emergency supplemental funding bill to provide military support to Israel in its war against Hamas terrorists.
The Economics of “Delinking” PBM Compensation
Pharmacy benefit managers (PBMs) are a popular Congressional target of late.
The Supreme Court Should Leave the Tax Code Alone
We have submitted an amicus brief in support of the respondent (the US government) arguing that the MRT is constitutional as an indirect tax.
Implications of Cannabis Legalization for the US Federal Budget
Federal legislation to legalize, regulate, and tax cannabis could have significant impacts on the federal budget.
Amicus Brief in Moore v. United States
In December, the Supreme Court will hear oral arguments in Moore v. United States, a case to determine whether the mandatory repatriation tax (MRT) is constitutional.
Biosimilars – Keys to Success in the Pharmacy Benefit
Alex Brill recently joined the GRx+Biosims 2023 conference panel to discuss biosimilars and the keys to success in the pharmacy benefit.
New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership
In a new white paper, Alex Brill details the consequences of regulatory uncertainty for businesses and provides a close look at the ongoing uncertainty facing companies owned by ESOPs.
MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate
MGA latest white paper, by CEO Alex Brill, looks at the role of pharmacy benefit managers (PBMs) in the US prescription drug market.
Unintended Consequences of Limiting PBMs
As Congress stumbles toward a government shutdown, health policy legislation continues to simmer in the background.
‘The Price of Business’: A Major Fiscal Crisis is Brewing and Largely Ignored by the Media
Alex Brill joined Kevin Price on ‘The Price of Business’ to discuss the fact that the US will add over $1 trillion to the deficit in a single year.
1 big thing: Congress takes on PBMs
“Alex Brill, CEO of the economic consulting firm Matrix Global Advisors and a senior fellow at AEI, said it is “unnecessary” to require PBMs to pass the rebates along to plans.”
Here comes Humira competition
MGA’s analysis of the competition as new adalimumab biosimilars enter market.
- The Child Tax Credit: Tradeoffs and Preferences
- Oregon’s Measure 118: The Turnover Tax Is the Worst
- Dueling Child Tax Credit Proposals: Harris vs. Vance
- Trump Proposes Bringing Back the Deduction for Auto Loan Interest
- Overtime Income Tax Break: Not Illogical, Just Costly and Complicated
- Presidential Candidates’ Dueling Child Credit Expansions Explained
- A Tip Exemption Is Not Sound Tax Policy
- Implications of Cannabis Legalization for the US Federal Budget
- Alex Brill Writes to FTC Regarding Interim Pharmacy Benefit Manager Report
- A Balanced Plan for Fiscal Stability and Economic Growth
